Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies.
作者信息
Lukacs-Kornek Veronika, Hendrikx Tim, Sutti Salvatore
机构信息
Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria.
出版信息
Front Immunol. 2024 Nov 1;15:1512363. doi: 10.3389/fimmu.2024.1512363. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies.社论：从非酒精性脂肪性肝炎到肝细胞癌过程中的炎症反应：致病机制及可能的治疗策略
Front Immunol. 2024 Nov 1;15:1512363. doi: 10.3389/fimmu.2024.1512363. eCollection 2024.
2
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.富含组氨酸糖蛋白在代谢功能障碍相关脂肪性肝炎相关疾病进展及肝癌发生中的作用
Front Immunol. 2024 Feb 26;15:1342404. doi: 10.3389/fimmu.2024.1342404. eCollection 2024.
3
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.非酒精性脂肪性肝病（MASLD）/非酒精性脂肪性肝炎（MASH）：是否有必要进行标记？全面的叙述性综述。
Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.
4
From MASH to HCC: the role of Gas6/TAM receptors.从 MASH 到 HCC：Gas6/TAM 受体的作用。
Front Immunol. 2024 Jan 17;15:1332818. doi: 10.3389/fimmu.2024.1332818. eCollection 2024.
5
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
6
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
7
Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.从代谢功能障碍相关脂肪性肝炎向肝细胞癌转变过程中的T细胞介导的适应性免疫
Front Cell Dev Biol. 2024 May 7;12:1343806. doi: 10.3389/fcell.2024.1343806. eCollection 2024.
8
Molecular mechanisms in MASLD/MASH-related HCC.与代谢相关脂肪性肝病/非酒精性脂肪性肝炎相关肝细胞癌的分子机制
Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000786.
9
The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).新冠病毒病（COVID-19）对代谢功能障碍相关脂肪性肝病（MASLD）进展的长期影响。
Cureus. 2023 Sep 14;15(9):e45231. doi: 10.7759/cureus.45231. eCollection 2023 Sep.
10
MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.与代谢相关脂肪性肝病相关的肝细胞癌——发病机制与当前治疗选择的最新进展
J Pers Med. 2024 Mar 30;14(4):370. doi: 10.3390/jpm14040370.
引用本文的文献
1
Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma.代谢功能障碍相关脂肪性肝病进展中的慢性炎症与免疫失调：从脂肪变性到肝细胞癌
Biomedicines. 2025 May 21;13(5):1260. doi: 10.3390/biomedicines13051260.
本文引用的文献
1
From MASLD to HCC: What's in the middle?从代谢相关脂肪性肝病到肝细胞癌：中间环节是什么？
Heliyon. 2024 Jul 31;10(15):e35338. doi: 10.1016/j.heliyon.2024.e35338. eCollection 2024 Aug 15.
2
Targeting nuclear receptors for NASH/MASH: From bench to bedside.针对非酒精性脂肪性肝炎/代谢相关脂肪性肝炎的核受体：从 bench 到 bedside。 （注：bench可理解为实验室研究阶段，bedside可理解为临床应用阶段 ，这里直接保留英文未完全意译，因为准确翻译这两个词在该语境下较难找到完全对应的精准中文表述，直接保留英文更能体现原文专业语境）
Liver Res. 2024 Mar;8(1):34-45. doi: 10.1016/j.livres.2024.03.002.
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
4
The role of hepatokines in NAFLD.肝分泌物在非酒精性脂肪性肝病中的作用。
Cell Metab. 2023 Feb 7;35(2):236-252. doi: 10.1016/j.cmet.2023.01.006.
5
Inflammatory processes involved in NASH-related hepatocellular carcinoma.与 NASH 相关的肝细胞癌中的炎症过程。
Biosci Rep. 2023 Jan 31;43(1). doi: 10.1042/BSR20221271.
6
Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis.氧化脂质：非酒精性脂肪性肝病和动脉粥样硬化常见的免疫原性驱动因素
Front Cardiovasc Med. 2022 Jan 10;8:824481. doi: 10.3389/fcvm.2021.824481. eCollection 2021.
7
Multiple Roles of Histidine-Rich Glycoprotein in Vascular Homeostasis and Angiogenesis.富含组氨酸的糖蛋白在血管稳态和血管生成中的多重作用。
Acta Med Okayama. 2021 Dec;75(6):671-675. doi: 10.18926/AMO/62805.
8
SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets.丝氨酸蛋白酶抑制剂B3在肝细胞癌中对缺氧诱导因子-1α和-2α的上调作用不同：揭示新潜在治疗靶点的机制
Cancers (Basel). 2019 Dec 4;11(12):1933. doi: 10.3390/cancers11121933.
9
Adaptive immunity: an emerging player in the progression of NAFLD.适应性免疫：非酒精性脂肪性肝病进展中的新兴参与者。
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92. doi: 10.1038/s41575-019-0210-2. Epub 2019 Oct 11.
10
Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases.蛋白酶激活受体（PARs）：PAR驱动的炎症性疾病中的作用机制及潜在治疗调节剂
Thromb J. 2019 Mar 29;17:4. doi: 10.1186/s12959-019-0194-8. eCollection 2019.
Zotero 插件